Skip to main content
Infliximab levels at induction may predict long-term response

Inflammatory bowel disease patients with lower trough levels of infliximab at induction may be less likely to respond to the drug during treatment maintenance, researchers reported in the journal Inflammatory Bowel Diseases. Up to 30% of IBD patients may see a loss of response over 12 months of treatment with infliximab, researchers said.

Full Story: